Soluble Prokaryotic Expression and Purification of Bioactive Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is considered as an antitumor agent owing to its ability to induce apoptosis of cancer cells without imparting toxicity toward most normal cells. TRAIL is produced in poor yield because of its insoluble expression in the cytoplasm of E. coli. In this study, we achieved soluble expression of TRAIL by fusing maltose-binding protein (MBP), b’a’ domain of protein disulfide isomerase (PDIb’a’), or protein disulfide isomerase at the N-terminus of TRAIL. The TRAIL was purified using subsequent immobilized metal affinity chromatography and amylose-binding chromatography, with the tag removal using tobacco etch virus protease. Approximately 4.5 mg of pure TRAIL was produced from 125 ml flask culture with a purification yield of 71.6%. The endotoxin level of the final product was 0.4 EU/μg, as measured by the Limulus amebocyte lysate endotoxin assay. The purified TRAIL was validated and shown to cause apoptosis of HeLa cells with an EC50 and Hill coefficient of 0.6 ± 0.03 nM and 2.41 ± 0.15, respectively. The high level of apoptosis in HeLa cells following administration of purified TRAIL indicates the significance and novelty of this method for producing high-grade and high-yield TRAIL.
Abstract
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is considered as an antitumor agent owing to its ability to induce apoptosis of cancer cells without imparting toxicity toward most normal cells. TRAIL is produced in poor yield because of its insoluble expression in the cytoplasm of E. coli. In this study, we achieved soluble expression of TRAIL by fusing maltose-binding protein (MBP), b’a’ domain of protein disulfide isomerase (PDIb’a’), or protein disulfide isomerase at the N-terminus of TRAIL. The TRAIL was purified using subsequent immobilized metal affinity chromatography and amylose-binding chromatography, with the tag removal using tobacco etch virus protease. Approximately 4.5 mg of pure TRAIL was produced from 125 ml flask culture with a purification yield of 71.6%. The endotoxin level of the final product was 0.4 EU/μg, as measured by the Limulus amebocyte lysate endotoxin assay. The purified TRAIL was validated and shown to cause apoptosis of HeLa cells with an EC50 and Hill coefficient of 0.6 ± 0.03 nM and 2.41 ± 0.15, respectively. The high level of apoptosis in HeLa cells following administration of purified TRAIL indicates the significance and novelty of this method for producing high-grade and high-yield TRAIL.
참고문헌 (45)
- Wang S, "TRAIL and apoptosis induction by TNF-family death receptors", Oncogene, 22, pp.8628~8633 (2003)
- Pitti RM, "Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family", J. Biol. Chem, 271, pp.12687~12690 (1996)
- Kimberley FC, "Following a TRAIL: update on a ligand and its five receptors", Cell Res, 14, pp.359~372 (2004)
- Malhi H, "TRAIL resistance results in cancer progression: a TRAIL to perdition?", Oncogene, 25, pp.7333~7335 (2006)
- Hymowitz SG, "A unique zinc-binding site revealed by a high-resolution X-ray structure of homotrimeric Apo2L", TRAIL, 2000, pp.39, 633~640
- Bodmer JL, "Cysteine 230 is essential for the structure and activity of the cytotoxic ligand TRAIL", J. Biol. Chem, 275, pp.20632~20637 (2000)
- Szliszka E, "TRAIL-induced apoptosis and expression of death receptor TRAIL-R1 and TRAIL-R2 in bladder cancer cells", Folia Histochem. Cytobiol, 47, pp.579~585 (2009)
- LeBlanc HN, "Apo2L", TRAIL and its death and decoy receptors, 2003, pp.10, 66~75
- Holen I, "Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells", Cancer Res, 62, pp.1619~1623 (2002)
- Seki N, "Tumor necrosis factor-related apoptosisinducing ligand-mediated apoptosis is an important endogenous mechanism for resistance to liver metastases in murine renal cancer", Cancer Res, 63, pp.207~213 (2003)
- Zhang XD, "Mechanisms of resistance of normal cells to TRAIL induced apoptosis vary between different cell types", FEBS Lett, 482, pp.193~199 (2000)
- Chandrasekaran S, "TRAIL-mediated apoptosis in breast cancer cells cultured as 3D spheroids", PLoS One, 9, pp.e111487~ (2014)
- Pan Y, "Evaluation of pharmacodynamic biomarkers in a Phase 1a trial of dulanermin (rhApo2L", TRAIL) in patients with advanced tumours, 2011, pp.105, 1830~1838
- Dimberg LY, "On the TRAIL to successful cancer therapy? Predicting and counteracting resistance against TRAIL-based therapeutics", Oncogene, 32, pp.1341~1350 (2013)
- Stuckey DW, "TRAIL on trial: preclinical advances in cancer therapy", Trends Mol. Med, 19, pp.685~694 (2013)
- Lim B, "Targeting TRAIL in the treatment of cancer: new developments", Expert Opin. Ther. Targets, 19, pp.1171~1185 (2015)
- Schneider P., "Production of recombinant TRAIL and TRAIL receptor: Fc chimeric proteins", Methods Enzymol, 322, pp.325~345 (2000)
- Cha SS, "Expression, purification and crystallization of recombinant human TRAIL", Acta Crystallogr. D Biol. Crystallogr, 55, pp.1101~1104 (1999)
- Gasparian ME, "Overexpression and refolding of thioredoxin", TRAIL fusion from inclusion bodies and further purification of TRAIL after cleavage by enteropeptidase, 2007, pp.29, 1567~1573
- Lin Z, "Expression, purification, and in vitro refolding of soluble tumor necrosis factor-related apoptosisinducing ligand (TRAIL)", Protein Expr. Purif, 51, pp.276~282 (2007)
- Wang D, "High-level expression, purification, and in vitro refolding of soluble tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)", Appl. Biochem. Biotechnol, 157, pp.1~9 (2009)
- Singh SM, "Solubilization and refolding of bacterial inclusion body proteins", J. Biosci. Bioeng, 99, pp.303~310 (2005)
- Li P, "Fed-batch production of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in soluble form in Escherichia coli and its purification and characterization", Protein Expr. Purif, 126, pp.115~121 (2016)
- Cha SS, "Crystal structure of TRAIL-DR5 complex identifies a critical role of the unique frame insertion in conferring recognition specificity", J. Biol. Chem, 275, pp.31171~31177 (2000)
- Vu TT, "Soluble overexpression and purification of bioactive human CCL2 in E. coli by maltose-binding protein", Mol. Biol. Rep, 42, pp.651~663 (2015)
- Nguyen MT, "Prokaryotic soluble overexpression and purification of human VEGF165 by fusion to a maltose binding protein tag", PLoS One, 11, pp.e0156296~ (2016)
- Rosano GL, "Recombinant protein expression in Escherichia coli: advances and challenges", Front. Microbiol, 5, pp.172~ (2014)
- Vera A, "The conformational quality of insoluble recombinant proteins is enhanced at low growth temperatures", Biotechnol. Bioeng, 96, pp.1101~1106 (2007)
- Schellman JA., "Temperature, stability, and the hydrophobic interaction", Biophys. J, 73, pp.2960~2964 (1997)
- Thiele JR, "Dissociation of pentameric to monomeric C-reactive protein localizes and aggravates inflammation: in vivo proof of a powerful proinflammatory mechanism and a new anti-inflammatory strategy", Circulation, 130, pp.35~50 (2014)
- Vu TT, "Soluble prokaryotic expression and purification of crotamine using an N-terminal maltose-binding protein tag", Toxicon Official J Int. Soc. Toxinol, 92, pp.157~165 (2014)
- Raran-Kurussi S, "The ability to enhance the solubility of its fusion partners is an intrinsic property of maltose-binding protein but their folding is either spontaneous or chaperone-mediated", PLoS One, 7, pp.e49589~ (2012)
- Liu Y, "Increase of soluble expression in Escherichia coli cytoplasm by a protein disulfide isomerase gene fusion system", Protein Expr. Purif, 44, pp.155~161 (2005)
- Nguyen MT, "Prokaryotic soluble overexpression and purification of bioactive human growth hormone by fusion to thioredoxin, maltose binding protein, and protein disulfide isomerase", PLoS One, 9, pp.e89038~ (2014)
- Shen YL, "Refolding and purification of Apo2l", TRAIL produced as inclusion bodies in high-cell-density cultures of recombinant Escherichia coli, 2003, pp.25, 2097~2101
- de Miguel D, "Onto better TRAILs for cancer treatment", Cell Death Differ, 23, pp.733~747 (2016)
- Trabzuni D, "Functional analysis of tumour necrosis factor-alpha-related apoptosisinducing ligand (TRAIL): cysteine-230 plays a critical role in the homotrimerization and biological activity of this novel tumoricidal cytokine", Biochem. J, 350, pp.505~510 (2000)
- Gasparian ME, "Generation of new TRAIL mutants DR5-A and DR5-B with improved selectivity to death receptor 5", Apoptosis, 14, pp.778~787 (2009)
- Li JH, "TRAIL induces apoptosis and inflammatory gene expression in human endothelial cells", J. Immunol, 171, pp.1526~1533 (2003)
- Qiu F, "Annexin V-TRAIL fusion protein is a more sensitive and potent apoptotic inducer for cancer therapy", Sci. Rep, 3, pp.3565~ (2013)
- Cao L, "Enhancement of antitumor properties of TRAIL by targeted delivery to the tumor neovasculature", Mol. Cancer Ther, 7, pp.851~861 (2008)
- Wiley SR, "Identification and characterization of a new member of the TNF family that induces apoptosis", Immunity, 3, pp.673~682 (1995)
- Kim SH, "Death induction by recombinant native TRAIL and its prevention by a caspase 9 inhibitor in primary human esophageal epithelial cells", J. Biol. Chem, 279, pp.40044~40052 (2004)
- van der Sloot AM, "Stabilization of TRAIL, an allbeta-sheet multimeric protein, using computational redesign", Protein Eng. Des. Sel, 17, pp.673~680 (2004)
- Pan LQ, "Hetero-modification of TRAIL trimer for improved drug delivery and in vivo antitumor activities", Sci. Rep, 5, pp.14872~ (2015)